A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Leukemia Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT06514794
Trial Phases:	Phase II	Protocol IDs:	WUC007-03 (primary) NCI-2025-00960
Eligibility:	1 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Allotera Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT06514794

Summary

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with
Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic
Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual
Disease (MRD) negative response

Objectives

This is a Phase 2, single-arm, multi-center, open label study in patients with R/R
T-ALL/LBL and T-ALL/LBL in remission but remaining MRD positive.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.